Modeling T cell dysfunction in tumor microenvironments

Online Inquiry

webinar recording 10 AM EDT | September 1, 2026

What makes tumor-infiltrating T cells lose function just when they are needed most? Inside tumors, intense metabolic competition can strip immune cells of essential nutrients and expose them to toxic byproducts, creating conditions that favor immune evasion.

Join Greg M. Delgoffe, Ph.D., Professor of Immunology at the University of Pittsburgh, to explore how metabolic and immunologic pressures reshape T cell function.

Discover how metabolically distinct tumor models can be reduced to defined immunologic and metabolic stressors, creating a clearer preclinical framework for studying T cell dysfunction.

Key points to be discussed during the session:

How nutrient depletion and metabolic byproducts contribute to immune evasion and T cell dysfunction
How metabolically distinct tumor models can be used to study the tumor microenvironment in a preclinical setting
How metabolic pressures can be reduced to defined immunologic and metabolic stressors

Webinar Recording

Speaker

Greg M. Delgoffe, Ph.D
Professor of Immunology, University of Pittsburgh

Greg M. Delgoffe, Ph.D is Professor of Immunology at the University of Pittsburgh, Associate Director for Basic Research and Director of the Tumor Microenvironment Center at the UPMC Hillman Cancer Center. Dr. Delgoffe obtained his Ph.D at Johns Hopkins School of Medicine in 2010, and completed postdoctoral training at St. Jude Children’s Research Hospital in 2014. Dr. Delgoffe’s lab has worked to both understand how immune cells alter their functional and differentiation state through integration of metabolic cues, most notably in cancer. He studies mechanisms by which T cells become metabolically insufficient as they infiltrate tumors and leverage that insight into strategies to metabolically bolster immunotherapy for cancer. Further, he works to understand how deleterious T cell populations in cancer, such as exhausted and regulatory T cells, are metabolically supported in cancer and inflamed tissue. He also has interests in how the immune system can be modulated metabolically through alterations to diet. Much of his work has been translated into both novel therapeutics and as well as repurposing metabolic drugs as immunometabolic agents to improve immunotherapy. Since 2022, he has been named a Clarivate Highly Cited Researcher in immunology and has received multiple awards including the NIH Director’s New Innovator Award and the Cancer Research Institute’s Lloyd J Old STAR Award. In 2023 he was elected to the National Academy of Inventors in part due to his dedication to translating immunometabolism discoveries to cancer therapies. Overall, the Delgoffe lab has worked to uncover and dissect the metabolic networks present in immunity and develop novel means to tip the metabolic balance in favor of curative immunity to cancer.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

Novel Solution. (Creative Biolabs Authorized)

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

New Technology. (Creative Biolabs Authorized)

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION